Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Jul 15. doi: 10.1158/1535-7163.MCT-18-1224. [Epub ahead of print]

PMID:
31308077
2.

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S.

Clin Sarcoma Res. 2019 Mar 5;9:3. doi: 10.1186/s13569-019-0112-7. eCollection 2019.

3.

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

Kaitsiotou H, Keul M, Hardick J, Mühlenberg T, Ketzer J, Ehrt C, Krüll J, Medda F, Koch O, Giordanetto F, Bauer S, Rauh D.

J Med Chem. 2017 Nov 9;60(21):8801-8815. doi: 10.1021/acs.jmedchem.7b00841. Epub 2017 Oct 24.

PMID:
28991465
4.

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.

Tomassi S, Lategahn J, Engel J, Keul M, Tumbrink HL, Ketzer J, Mühlenberg T, Baumann M, Schultz-Fademrecht C, Bauer S, Rauh D.

J Med Chem. 2017 Mar 23;60(6):2361-2372. doi: 10.1021/acs.jmedchem.6b01626. Epub 2017 Mar 10.

PMID:
28225269
5.

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR.

Engel J, Becker C, Lategahn J, Keul M, Ketzer J, Mühlenberg T, Kollipara L, Schultz-Fademrecht C, Zahedi RP, Bauer S, Rauh D.

Angew Chem Int Ed Engl. 2016 Aug 26;55(36):10909-12. doi: 10.1002/anie.201605011. Epub 2016 Aug 5.

PMID:
27496389
6.

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.

Falkenhorst J, Grunewald S, Mühlenberg T, Marino-Enriquez A, Reis AC, Corless C, Heinrich M, Treckmann J, Podleska LE, Schuler M, Fletcher JA, Bauer S.

Oncotarget. 2016 Jul 5;7(27):41390-41403. doi: 10.18632/oncotarget.9159.

7.

Covalent-Allosteric Kinase Inhibitors.

Weisner J, Gontla R, van der Westhuizen L, Oeck S, Ketzer J, Janning P, Richters A, Mühlenberg T, Fang Z, Taher A, Jendrossek V, Pelly SC, Bauer S, van Otterlo WA, Rauh D.

Angew Chem Int Ed Engl. 2015 Aug 24;54(35):10313-6. doi: 10.1002/anie.201502142. Epub 2015 Jun 25.

PMID:
26110718
8.

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.

Mühlenberg T, Grunewald S, Treckmann J, Podleska L, Schuler M, Fletcher JA, Bauer S.

PLoS One. 2015 Mar 17;10(3):e0120531. doi: 10.1371/journal.pone.0120531. eCollection 2015.

9.

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.

Bauer S, Hilger RA, Mühlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, Reichardt A, Ahrens M, Reichardt P, Grunewald S, Scheulen ME, Pustowka A, Bock E, Schuler M, Pink D.

Br J Cancer. 2014 Mar 4;110(5):1155-62. doi: 10.1038/bjc.2013.826. Epub 2014 Jan 16.

10.

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Edris B, Willingham S, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Weissman IL, van de Rijn M.

Oncoimmunology. 2013 Jun 1;2(6):e24452. Epub 2013 May 14.

11.

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S.

Cancer Res. 2013 Jun 15;73(12):3661-70. doi: 10.1158/0008-5472.CAN-12-3839. Epub 2013 Apr 10.

12.

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. doi: 10.1073/pnas.1222893110. Epub 2013 Feb 4.

13.

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.

Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, Fletcher JA, Bauer S.

PLoS One. 2012;7(5):e37776. doi: 10.1371/journal.pone.0037776. Epub 2012 May 25.

14.

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.

Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, Fletcher JA, Beck AH, West RB, Nusse R, van de Rijn M.

J Pathol. 2012 Jun;227(2):223-33. doi: 10.1002/path.3986. Epub 2012 Feb 17.

15.

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.

Bauer S, Parry JA, Mühlenberg T, Brown MF, Seneviratne D, Chatterjee P, Chin A, Rubin BP, Kuan SF, Fletcher JA, Duensing S, Duensing A.

Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.

16.

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.

Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S.

Cancer Res. 2009 Sep 1;69(17):6941-50. doi: 10.1158/0008-5472.CAN-08-4004. Epub 2009 Aug 25.

17.

Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.

Bauer S, Mühlenberg T, Leahy M, Hoiczyk M, Gauler T, Schuler M, Looijenga L.

Eur Urol. 2010 Apr;57(4):679-87. doi: 10.1016/j.eururo.2009.06.014. Epub 2009 Jun 21.

PMID:
19560254

Supplemental Content

Loading ...
Support Center